Giuseppe Tarantini

Apr 22, 2024 | jacc.org | Giuseppe Tarantini |Luca Nai Fovino

References1. "Quality of life 5 years following transfemoral TAVR or SAVR in intermediate risk patients". J Am Coll Cardiol Intv . 2024;17:8: 979-988. 2. "Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) trial (Cohort A)". J Am Coll Cardiol . 2012;60:6: 548-558. https://doi.org/10.1016/j.jacc.2012.03.075. 3.

Feb 5, 2024 | eurointervention.pcronline.com | Giuseppe Tarantini |Gilbert H. Tang |Luca Nai Fovino |Daniel Blackman

Introduction Transcatheter aortic valve implantation (TAVI) is an established therapy for elderly patients with severe symptomatic aortic valve stenosis (AS), irrespective of surgical risk123. The burden of coronary artery disease (CAD) is significant in patients with severe AS and may impact both the procedural risk as well as the post-procedural prognosis of the patient.